Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Primary Myelofibrosis 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Graft vs Host Disease 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 16Mycophenolic Acid 13Tacrolimus 10fludarabine 9ruxolitinib 8Busulfan 7fludarabine phosphate 6Whole-Body Irradiation 6Sirolimus 6Melphalan 6Methotrexate 5Thiotepa 4ibrutinib 3Specimen Handling 3Cyclosporine 3Abatacept 3Stem Cell Transplantation 2Radiotherapy 2Hematopoietic Stem Cell Transplantation 2Clofarabine 2Biopsy 2vedolizumab 1tildrakizumab 1itacitinib 1blinatumomab 1belumosudil 1axatilimab 1Vorinostat 1Therapeutics 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Graft vs Host Disease × axatilimab × 1 year × Clear all
NCT04710576 2026-03-16

AGAVE-201

Syndax Pharmaceuticals

Phase 2 Active not recruiting
241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡